Astellas Pharma (4503) AI Stock Analysis

• Market Cap: ¥3.83T
• Dividend Yield: 3.57%
• Average Volume (3M): 8.81M
• Price to Earnings (P/E): 30.5
• Beta (1Y): 0.47
• Revenue Growth: 13.24%
• EPS Growth: 127.88%
• Country: JP
• Employees: 14,754
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 44.22
• Shares Outstanding: 1,809,663,100
• 10 Day Avg. Volume: 7,694,500
• 30 Day Avg. Volume: 8,807,129
• PEG Ratio: 0.26
• Price to Book (P/B): 1.71
• Price to Sales (P/S): 1.35
• P/FCF Ratio: 15.73
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥1,924.93
• Price Target Upside: -2.01% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): 96.4
• Revenue Forecast (FY): ¥2.02T

• Rating: 69 Neutral
• Price Target: ¥2,271.00 ▲(15.60% Upside)

Astellas Pharma's overall stock score is driven by its strong financial performance and robust cash flow generation, which are key strengths. The technical analysis indicates bullish momentum but also highlights overbought conditions, suggesting caution. The valuation is relatively high, which could limit upside potential. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates a positive market trajectory and strong demand for Astellas' products, supporting long-term business expansion.

Cash Flow Generation

Strong cash flow generation enhances financial flexibility, enabling Astellas to invest in R&D, strategic acquisitions, and debt servicing.

Profitability

High profitability margins reflect efficient cost management and strong operational performance, ensuring sustainable earnings growth.

Negative Factors

High Debt Levels

Elevated debt levels can strain financial resources, potentially impacting Astellas' ability to invest in growth opportunities and manage economic downturns.

Leverage Concerns

While leverage has improved, high debt levels remain a concern, potentially limiting financial flexibility and increasing vulnerability to interest rate hikes.

Valuation Concerns

A high valuation may limit upside potential and make the stock less attractive to value-focused investors, impacting long-term investment appeal.

Astellas Pharma Business Overview & Revenue Model

Company Description

Astellas Pharma Inc. is a global pharmaceutical company headquartered in Tokyo, Japan. Established in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical, Astellas focuses on the research, development, manufacture, and marketing of prescription drugs. The company operates in several therapeutic areas, primarily including urology, oncology, immunology, neuroscience, and infection. Astellas is known for its innovative products such as Xtandi (enzalutamide) for prostate cancer and Advagraf (tacrolimus) for organ transplant patients, among others.

How the Company Makes Money

Astellas Pharma generates revenue primarily through the sale of prescription medications and biologics. The company has a diverse portfolio of products that contribute to its earnings, with key revenue streams coming from high-demand therapies in oncology and urology. Astellas also engages in research and development collaborations and licensing agreements with other pharmaceutical companies, which can provide additional income through upfront payments, milestone payments, and royalties on sales of partnered products. Moreover, the company invests in strategic partnerships to enhance its pipeline, further solidifying its revenue base. Astellas' commitment to innovation, driven by significant investments in R&D, allows it to capitalize on market opportunities and address unmet medical needs, thereby sustaining its profitability.

Astellas Pharma Financial Statement Overview

Summary

Astellas Pharma exhibits strong financial health with consistent revenue growth, improving profitability, and robust cash flow generation. The balance sheet reflects moderate leverage and strong equity, supporting long-term stability.

Income Statement

Astellas Pharma demonstrates strong revenue growth with a TTM increase of 1.71% and consistent gross profit margins above 74%. The net profit margin has improved to 4.19% in the TTM, indicating enhanced profitability. However, the EBIT margin shows a significant increase from previous periods, suggesting improved operational efficiency.

Balance Sheet

The company's debt-to-equity ratio remains stable at 0.60, reflecting moderate leverage. Return on equity has improved to 5.42% in the TTM, indicating better utilization of equity. The equity ratio is healthy, suggesting a strong equity base relative to total assets.

Cash Flow

Astellas Pharma's free cash flow growth is robust at 26.85% in the TTM, indicating strong cash generation capabilities. The operating cash flow to net income ratio is 0.22, showing efficient conversion of income to cash. The free cash flow to net income ratio is high at 0.85, reflecting strong cash flow relative to earnings.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.01T	1.91T	1.60T	1.52T	1.30T	1.25T
Gross Profit	1.57T	1.43T	1.31T	1.23T	1.04T	1.00T
EBITDA	543.85B	248.30B	195.34B	240.46B	241.03B	219.83B
Net Income	124.87B	50.75B	17.05B	98.71B	124.09B	120.59B
Balance Sheet
Total Assets	3.45T	3.34T	3.57T	2.46T	2.33T	2.27T
Cash, Cash Equivalents and Short-Term Investments	287.05B	188.37B	335.69B	376.84B	315.99B	326.13B
Total Debt	740.54B	831.43B	1.01T	200.01B	212.74B	278.26B
Total Liabilities	1.84T	1.83T	1.97T	948.56B	872.09B	887.51B
Stockholders Equity	1.61T	1.51T	1.60T	1.51T	1.46T	1.39T
Cash Flow
Free Cash Flow	369.56B	164.61B	89.98B	239.23B	181.00B	229.40B
Operating Cash Flow	403.20B	201.61B	172.47B	327.77B	257.44B	306.84B
Investing Cash Flow	-69.61B	-89.42B	-845.80B	-84.50B	-62.41B	-81.89B
Financing Cash Flow	-350.90B	-261.37B	614.06B	-195.62B	-216.30B	-229.48B

Astellas Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1964.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4503, the sentiment is Positive. The current price of 1964.5 is below the 20-day moving average (MA) of 2012.52, above the 50-day MA of 1818.35, and above the 200-day MA of 1536.03, indicating a bullish trend. The MACD of 79.24 indicates Negative momentum. The RSI at 77.53 is Negative, neither overbought nor oversold. The STOCH value of 90.15 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4503.

Astellas Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4528	75 Outperform	¥1.03T	21.30	6.03%	3.64%	4.00%	-48.73%
4507	75 Outperform	¥2.43T	13.76	12.22%	2.24%	4.48%	11.08%
4523	74 Outperform	¥1.30T	26.39	5.75%	3.54%	6.79%	22.14%
4519	74 Outperform	¥13.60T	34.26	20.99%	1.18%	6.25%	2.62%
4503	69 Neutral	¥3.83T	30.49	7.97%	3.57%	13.24%	127.88%
4568	63 Neutral	¥6.35T	22.70	16.66%	2.03%	12.56%	14.58%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Astellas Pharma Corporate Events

Astellas Pharma Revises FY2025 Financial Forecasts Upward

Astellas Pharma has revised its financial forecasts for FY2025, projecting higher revenues and profits due to the strong performance of its strategic brands, including VYLOY™ for gastric cancer, PADCEV™ for urothelial cancer, and XTANDI™ for prostate cancer. The company’s cost management initiative, Sustainable Margin Transformation, is also expected to positively impact its financial performance, highlighting Astellas’ robust market positioning and strategic growth in the life sciences sector.

Astellas Pharma’s GLEAM Trial Falls Short of Primary Endpoint in Pancreatic Cancer Study

Astellas Pharma announced that its Phase 2 GLEAM trial, which investigated the combination of zolbetuximab with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer, did not meet its primary endpoint of overall survival. Despite this setback, Astellas remains committed to advancing its research in pancreatic cancer, recognizing the significant challenges associated with this aggressive disease. The company plans to further evaluate the trial data and continue its efforts to develop innovative treatments, with the financial impact of the trial’s outcome expected to be minor.

Astellas Pharma’s IZERVAY Gains Conditional Approval in Japan for Geographic Atrophy

Astellas Pharma has received conditional approval from the Japanese Ministry of Health, Labor and Welfare for IZERVAY, making it the first approved treatment for suppressing geographic atrophy growth in age-related macular degeneration in Japan. This approval, achieved through an expedited pathway, is expected to significantly impact the treatment landscape for the estimated 100,000 people in Japan affected by this condition, potentially reducing the progression of visual impairment and enhancing patient access to innovative therapies.